Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia

Efrosyni Apostolidou, Elihu Estey, Jorge Cortes, Guillermo Garcia-Manero, Stefan Faderl, Deborah Thomas, Apostolia Tsimberidou, Hagop Kantarjian, Francis J. Giles

Research output: Contribution to journalArticle

Abstract

In a recent phase I study, a combination of gemcitabine at 10mg/(m2min) for 12h and mitoxantrone 12mg/m2 daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refractory acute myeloid leukemia (AML). In a cohort of 18 patients with very refractory disease (6 primary refractory, 12 relapsed, mean initial CR duration 3.5 months), one patient achieved a CR, a second CR with incomplete platelet recovery (CRp). Sepsis and mucositis were significant extramedullary toxicities. The gemcitabine and mitoxantrone regimen was feasible to administer even in heavily pre-treated patients. It was not active in patients who had failed a prior salvage regimen. It may warrant further study in patients with primary resistant AML.

Original languageEnglish (US)
Pages (from-to)301-304
Number of pages4
JournalLeukemia Research
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

gemcitabine
Salvage Therapy
Mitoxantrone
Acute Myeloid Leukemia
Mucositis
Sepsis
Leukemia
Blood Platelets

Keywords

  • Gemcitabine infusion
  • Mitoxantrone
  • Refractory myeloid leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. / Apostolidou, Efrosyni; Estey, Elihu; Cortes, Jorge; Garcia-Manero, Guillermo; Faderl, Stefan; Thomas, Deborah; Tsimberidou, Apostolia; Kantarjian, Hagop; Giles, Francis J.

In: Leukemia Research, Vol. 27, No. 4, 01.04.2003, p. 301-304.

Research output: Contribution to journalArticle

Apostolidou, E, Estey, E, Cortes, J, Garcia-Manero, G, Faderl, S, Thomas, D, Tsimberidou, A, Kantarjian, H & Giles, FJ 2003, 'Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia', Leukemia Research, vol. 27, no. 4, pp. 301-304. https://doi.org/10.1016/S0145-2126(02)00171-6
Apostolidou, Efrosyni ; Estey, Elihu ; Cortes, Jorge ; Garcia-Manero, Guillermo ; Faderl, Stefan ; Thomas, Deborah ; Tsimberidou, Apostolia ; Kantarjian, Hagop ; Giles, Francis J. / Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. In: Leukemia Research. 2003 ; Vol. 27, No. 4. pp. 301-304.
@article{52ea30c7e98c44bda499f4185faa7c81,
title = "Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia",
abstract = "In a recent phase I study, a combination of gemcitabine at 10mg/(m2min) for 12h and mitoxantrone 12mg/m2 daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25{\%}) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refractory acute myeloid leukemia (AML). In a cohort of 18 patients with very refractory disease (6 primary refractory, 12 relapsed, mean initial CR duration 3.5 months), one patient achieved a CR, a second CR with incomplete platelet recovery (CRp). Sepsis and mucositis were significant extramedullary toxicities. The gemcitabine and mitoxantrone regimen was feasible to administer even in heavily pre-treated patients. It was not active in patients who had failed a prior salvage regimen. It may warrant further study in patients with primary resistant AML.",
keywords = "Gemcitabine infusion, Mitoxantrone, Refractory myeloid leukemia",
author = "Efrosyni Apostolidou and Elihu Estey and Jorge Cortes and Guillermo Garcia-Manero and Stefan Faderl and Deborah Thomas and Apostolia Tsimberidou and Hagop Kantarjian and Giles, {Francis J.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0145-2126(02)00171-6",
language = "English (US)",
volume = "27",
pages = "301--304",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia

AU - Apostolidou, Efrosyni

AU - Estey, Elihu

AU - Cortes, Jorge

AU - Garcia-Manero, Guillermo

AU - Faderl, Stefan

AU - Thomas, Deborah

AU - Tsimberidou, Apostolia

AU - Kantarjian, Hagop

AU - Giles, Francis J.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - In a recent phase I study, a combination of gemcitabine at 10mg/(m2min) for 12h and mitoxantrone 12mg/m2 daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refractory acute myeloid leukemia (AML). In a cohort of 18 patients with very refractory disease (6 primary refractory, 12 relapsed, mean initial CR duration 3.5 months), one patient achieved a CR, a second CR with incomplete platelet recovery (CRp). Sepsis and mucositis were significant extramedullary toxicities. The gemcitabine and mitoxantrone regimen was feasible to administer even in heavily pre-treated patients. It was not active in patients who had failed a prior salvage regimen. It may warrant further study in patients with primary resistant AML.

AB - In a recent phase I study, a combination of gemcitabine at 10mg/(m2min) for 12h and mitoxantrone 12mg/m2 daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refractory acute myeloid leukemia (AML). In a cohort of 18 patients with very refractory disease (6 primary refractory, 12 relapsed, mean initial CR duration 3.5 months), one patient achieved a CR, a second CR with incomplete platelet recovery (CRp). Sepsis and mucositis were significant extramedullary toxicities. The gemcitabine and mitoxantrone regimen was feasible to administer even in heavily pre-treated patients. It was not active in patients who had failed a prior salvage regimen. It may warrant further study in patients with primary resistant AML.

KW - Gemcitabine infusion

KW - Mitoxantrone

KW - Refractory myeloid leukemia

UR - http://www.scopus.com/inward/record.url?scp=0037377316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037377316&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00171-6

DO - 10.1016/S0145-2126(02)00171-6

M3 - Article

C2 - 12531220

AN - SCOPUS:0037377316

VL - 27

SP - 301

EP - 304

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -